AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:01 2024-07-05 am EDT			5-day change	1st Jan Change
12,056 ^GBX	-0.41%		-2.43%	+13.74%

Jul. 05	AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	MT
Jul. 05	AstraZeneca: cancer treatment approved by the EU	CF

ASTRAZENECA : Gets a Sell rating from UBS

June 04, 2024 at 05:54 am EDT

UBS reiterate its Sell rating. The target price is unchanged at GBX 11300.

Latest news about AstraZeneca PLC

AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	Jul. 05	MT
AstraZeneca: cancer treatment approved by the EU	Jul. 05	CF
AstraZeneca drug Tagrisso gets EU approval for cancer form	Jul. 05	AN
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment	Jul. 05	MT
ASTRAZENECA : Goldman Sachs maintains a Buy rating	Jul. 04	ZD
ASTRAZENECA : Buy rating from Berenberg	Jul. 03	ZD
Aptamer shares jump as inks agreement with AstraZeneca	Jul. 03	AN
Aptamer Group plc Announces New Agreement with AstraZeneca to Evaluate the Optimer Fibrotic Liver Delivery Vehicles for the Targeted Delivery of SiRNA	Jul. 03	CI
ASTRAZENECA : Jefferies reaffirms its Neutral rating	Jul. 02	ZD
Deutsche Bank cuts Quilter, ups Polar Capital	Jul. 02	AN
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June	Jul. 01	MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone	Jul. 01	MT
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment	Jul. 01	MT
AstraZeneca's Imfinzi, Lynparza Combination Recommended for Approval in Europe as Endometrial Cancer Treatment	Jul. 01	MT
AstraZeneca applies to the EMA for a Covid antibody	Jul. 01	CF
AstraZeneca: CHMP recommends Imfinzi and Lynparza	Jul. 01	CF
Stocks called higher ahead of Thursday's election	Jul. 01	AN
AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application	Jul. 01	MT
AstraZeneca's Application for COVID-19 Prevention Drug Wins Accelerated Review in EU	Jul. 01	MT
AstraZeneca's COVID prevention drug application gets EU fast-track assessment	Jul. 01	RE
AstraZeneca Plc's Lynparza & Imfinzi Announces Positive CHMP in Endometrial	Jul. 01	CI
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	Jun. 27	RE
European Equities Close Lower in Wednesday Trading	Jun. 26	MT
ASTRAZENECA : Deutsche Bank sticks Neutral	Jun. 26	ZD
AstraZeneca Says Tagrisso With Chemotherapy Approved in China	Jun. 26	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

154.4 USD

Average target price

174.6 USD

Spread / Average Target

+13.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.74%	239B
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B
PFIZER, INC.	-2.57%	159B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Gets a Sell rating from UBS

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals